Trials
1 active
1 in total
What this is
- How it works
- Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator FDA class
- Tested for
- CDKL5 Deficiency Disorder
- Main trialPhase 3
- “The goal of this clinical trial is to learn how patients with CDKL-5 deficiency disorder (CDD) aged 6 months to 2 years of age respond to treatment with ganaxolone. The main questions the trial aims to answer are: * The amount of the medicine that was in participants' bodies and the safety of the medicine. * Does the medicine ganaxolone lower the number of seizures when used in addition to the participant's usual anti-seizure treatment. Participants will: Take ganaxolone 3 times daily for up to 52 weeks. Visit the clinic every 3 to 5 weeks for the initial 17 weeks of the trial and…”In the company’s words, NCT05249556 on ClinicalTrials.gov
- Other names
- Ztalmy · Active Drug
Other drugs for CDKL5 Deficiency Disorder
- ZX008Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. · Phase 3
Coming up1
- Dec 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | Dec 2029 | Open-label, Single-arm Trial of Ganaxolone in CDD Patients 6 Months to Less Than 2 Years Old |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026